Societe Civile Bioprojet

Institut National De La Sante Et De La Recherche Medicale

Bioprojet

Other

Motac Neuroscience Limited

Societe Civile Bioproject

Holger Stark

Jean-Charles Schwartz

Jeanne-Marie Lecomte

Jean-Michel Arrang

Walter Schunack

Monique Garbarg

Xavier Ligneau

Charon R Ganellin

Ralph Lipp

Katja Purand

Antonio Guglietta

Manuel M Raga

Juan Sallares

Sigurd Elz

Abdellatif Fkyerat

Fabien Leurquin

Marta Guerrero

Wasyl Tertiuk

Charon Ganellin

Michael Peter Hill

Britta Caroline Sasse

Michael C O Krause

Sadek Bassem

Wasyl Tertiux

Charon Robbin Ganellin

Nadia Pelloux-Leon

Athmani Salah

Reidemeister Sybille

Annette Huls

Walter G Schunack

Agnes Quemener

Tim Kottke

Oliver Saur

Jukka Matti Leppanen

A compound of formal (I) is described: wherein Rand Rare as defined in the text and wherein the compounds are intended for use in treating medical conditions characterized by an imbalance in dopamine receptor activity.

Medicaments

A method is provided for the treatment of sleep apnea and other conditions wherein an effective amount of crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride of formula (I): optionally comprising water up to 6%, and having an X-ray diffractogram that comprises characteristic peaks (2&#x3b8;) at 11.2&#xb0;, 19.9&#xb0;, 20.7&#xb0; and 34.1&#xb0;&#xb1;0.2&#xb0; is administered to a patient in need thereof.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy]propyl]-piperidine

The invention relates to new crystalline 1-[3-[3-(4-chlorophenyl)propoxy]propyl]-piperidine monohydrochloride, the respective manufacture and methods of use, and compositions containing such a compound.

Monohydrochloride salt of 1-[3-[3-(4-chlorophenyl) propoxy] propyl] -piperidine

Use of a compound of formula (A), wherein: W is a residue which imparts antagonistic and/or agonistic activity at histamine H-receptors when attached to an imidazole ring in 4(5) position; Rand Rmay be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are attached, a saturated nitrogen-containing ring (i) as defined, a non-aromatic unsaturated nitrogen-containing ring (ii) as defined, a morpholino group, or a N-substituted piperazino group as defined for preparing medicaments acting as antagonists and/or agonists at the H-receptors of histamine.

[object Object]

Novel imidazole derivatives as histamine receptor H,antagonists and/or agonists, preparation thereof and therapeutical uses thereof. Chemical compounds for use as histamine receptor H,agonists, partial agonists or antagonists, having general formula (Ia) or (Ib), the use thereof for making drugs, and methods for revealing the agonist, partial agonist or antagonist activity of such compounds in vivo, are disclosed.

Imidazole derivatives as histamine receptor H3 (ANT) agonists

A compound selected from the group consisting of a compound of the formula ##STR1## having antagonist properties to histamine H.sub.3 -receptors.

Imidazole derivatives for pharmaceutical use

Imidazole compounds and their therapeutic applications

Azomethines agonist compounds of the histamine H.sub.3 receptor for

Growing community of inventors

Bad Homburg, Germany

Holger Stark